Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.38 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.37 |
| ▸ | SUV39H2 | Q9H5I1 | 4/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CKS1B | P61024 | 1/20 | 0.34 |
| ▸ | SKP1 | P63208 | 1/20 | 0.34 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4098247 | 0.79 | KDM4E (0.53) | JAK3BTKP2RY12SUV39H2KDM4E | |
| SCHEMBL4877982 | 0.75 | KDM4E (0.58) | P2RY12KDM4E | |
| SCHEMBL19734311 | 0.75 | JAK3 (0.50) | JAK3BTKCTSKPDE10AKCNA3 | |
| SCHEMBL29658714 | 0.75 | JAK3 (0.50) | JAK3BTKCTSKPDE10AKCNA3 | |
| SCHEMBL3933313 | 0.74 | P2RY12 (0.64) | P2RY12KDM4E | |
| SCHEMBL4878271 | 0.74 | KDM4E (0.54) | P2RY12KDM4E | |
| SCHEMBL4115267 | 0.72 | P2RY12 (0.55) | P2RY12KDM4E | |
| SCHEMBL24951335 | 0.68 | PDE10A (0.56) | BTKPDE10AMAP4K4CKS1BSKP1 | |
| SCHEMBL30202103 | 0.68 | PDE10A (0.56) | BTKPDE10AMAP4K4CKS1BSKP1 | |
| SCHEMBL30819455 | 0.68 | PDE10A (0.56) | BTKPDE10AMAP4K4CKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312208-A1 | Pyridine Analogues | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312208-A1 | Pyridine Analogues | P2RY12, P2RY11, P2RY1 | JAK3 758/4885BTK 175/4885CTSK 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.